A New Approach to Molecular Monitoring in AML/CML, Single-Molecule Counting PCR Across BCR::ABL1, KMT2A, and Beyond
A New Approach to Molecular Monitoring in AML/CML, Single-Molecule Counting PCR Across BCR::ABL1, KMT2A, and Beyond
.png)
Summary
Molecular leukemia testing forces a trade-off: broad mutation/fusion coverage or deep MRD sensitivity — rarely both, and rarely from the limited samples pediatric and relapse cases provide. Countable Labs' new Ancora Heme Oncology assay menu removes those trade-offs enabling multiplexed, standard-curve-free quantification of BCR::ABL1, NPM1mut, KMT2A-r, and KIT D816V.
In this webinar:
- Pamela Ward (University of Southern California) shares clinical-sample data on the BCR::ABL1 assay: tighter precision than RT-PCR, independent double-transcript quantification, and longitudinal p230 monitoring
- Dongbin Xu (HematoLogics, Inc.) shares a highly multiplexed KMT2A-r assay covering 90–95% of fusion partners, plus how single-molecule counting extends coverage and sensitivity across the menu
For Research Use Only. Not for use in diagnostic procedures.
Key Topics
- How one platform consolidates the leukemia menu (BCR::ABL1, NPM1mut, KMT2A-r, KIT D816V), cutting trade-offs across coverage, sensitivity, sample, and cost
- Clinical evidence for the flagship BCR::ABL1 assay: RT-PCR precision comparison, isoform coverage, double-transcript/p230 cases
- Why multiplexed KMT2A-r detection matters, screening common fusions in one tube from limited sample, where single-plex RT-PCR falls short
